Hematological remission and long term hematological control of acute myeloblastic leukemia induced and maintained by granulocyte-colony stimulating factor (G-CSF) therapy.
D015703:Antigens, CD / Q000096:biosynthesis; D018952:Antigens, CD34 / Q000096:biosynthesis; D015214:Antigens, Differentiation, Myelomonocytic / Q000096:biosynthesis; D018826:CD13 Antigens / Q000096:biosynthesis; D004253:DNA Nucleotidylexotransferase / Q000096:biosynthesis; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000628:therapy; D008875:Middle Aged; D009195:Peroxidase / Q000378:metabolism; D010641:Phenotype; D012074:Remission Induction; D063268:Sialic Acid Binding Ig-like Lectin 3; D013997:Time Factors; D016896:Treatment Outcome
D015703:Antigens, CD; D018952:Antigens, CD34; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3; D016179:Granulocyte Colony-Stimulating Factor; D009195:Peroxidase; D004253:DNA Nucleotidylexotransferase; D018826:CD13 Antigens